NCT02964013View on ClinicalTrials.gov

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions
Neoplasms
Interventions
BIOLOGICAL

vibostolimab

Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35

BIOLOGICAL

pembrolizumab

Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

DRUG

pemetrexed

Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

DRUG

carboplatin

Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

BIOLOGICAL

pembrolizumab/vibostolimab coformulation

Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35

DRUG

cisplatin

Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4

DRUG

etoposide

Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02964013 - Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) | Biotech Hunter | Biotech Hunter